Last reviewed · How we verify
Glucose 25% oral solution
Glucose 25% oral solution provides a concentrated source of glucose to rapidly raise blood sugar levels in hypoglycemic patients.
Glucose 25% oral solution provides a concentrated source of glucose to rapidly raise blood sugar levels in hypoglycemic patients. Used for Acute hypoglycemia treatment, Symptomatic low blood sugar in pediatric and adult patients.
At a glance
| Generic name | Glucose 25% oral solution |
|---|---|
| Also known as | glucose, Water for injection, water for injection once per os |
| Sponsor | Children's & Women's Health Centre of British Columbia |
| Drug class | Carbohydrate supplement |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
This is a simple carbohydrate replacement therapy that delivers glucose directly into the bloodstream via oral absorption. It is used to treat acute hypoglycemia (low blood sugar) by providing readily available glucose that can be quickly metabolized to restore normal blood glucose levels. The 25% concentration allows for rapid absorption and fast symptom relief in hypoglycemic episodes.
Approved indications
- Acute hypoglycemia treatment
- Symptomatic low blood sugar in pediatric and adult patients
Common side effects
- Hyperglycemia (rebound high blood sugar)
- Gastrointestinal upset
- Nausea
Key clinical trials
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- Effect of Insulin Lowering on Lipogenesis (PHASE1)
- Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers (PHASE1)
- tVNS, Motivation, and Insulin Sensitivity (NA)
- A Multidisciplinary Perioperative Pain Management (NA)
- Whey Protein Pre-load and Postprandial Glycemia in Pregnancy (NA)
- Preoperative Carbohydrate Loading in Diabetes Mellitus (NA)
- Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: